Sernova (SVA) AI Stock Analysis

• Market Cap: C$47.14M
• Dividend Yield: N/A
• Average Volume (3M): 125.66K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: N/A
• EPS Growth: 54.38%
• Country: CA
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 336,698,550
• 10 Day Avg. Volume: 126,270
• 30 Day Avg. Volume: 125,661
• PEG Ratio: 0.06
• Price to Book (P/B): -1.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.02
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.15 ▼(-2.67% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is held back primarily by weak financial fundamentals (pre-revenue losses, negative equity, higher debt, and ongoing funding needs). Technicals are also bearish with the price below key moving averages, partially offset by oversold signals. Corporate events provide a modest uplift due to financing and debt-to-equity conversion, while valuation remains constrained by ongoing losses and no dividend.

Positive Factors

Proprietary Cell Pouch technology

Sernova’s Cell Pouch System is a platform implantable device creating a vascularized pocket for therapeutic cells, giving the company a durable, platform-level competitive angle in cell-based therapies for chronic diseases like diabetes. Platform orientation supports multiple indications and long-term strategic optionality around licensing or partnering once clinical efficacy is proven.

Meaningful reduction in operating losses

The company has materially reduced operating cash burn and net losses over two years, reflecting tighter cost control or program prioritization. Sustained downward trend in burn increases the likelihood management can extend runway from existing capital or smaller financings, improving the odds of executing near-term clinical milestones without as large periodic dilution events.

Recent financing and debt-to-equity conversion

The CAD ~$13.3M debt-to-equity conversion and additional financings materially reduce immediate cash-flow obligations and improve liquidity structure. Structurally this lowers near-term refinancing pressure, supports continuation of clinical programs, and makes future partner discussions or milestone-driven funding more viable versus pre-conversion debt burden.

Negative Factors

Pre-revenue development profile

Sernova remains pre-revenue, meaning it lacks product-derived cash flow and must fund operations via capital markets or partners. Over a multi-month horizon this structurally elevates financing and execution risk: until commercial sales or licensing occur, the business depends on external funding, which can dilute shareholders and constrain long-term planning.

Deteriorated balance sheet and negative equity

The shift to materially negative equity, higher debt and very low reported assets signals weakened financial resilience. Structurally this restricts borrowing capacity, raises refinancing and covenant risk, and increases the likelihood of future dilutive financings or asset sales to fund trials, which can impede steady clinical development and strategic independence.

Persistent negative free cash flow

Despite burn improvement, free cash flow remains negative and worsened year-over-year, indicating structural inability to self-fund. Over the next several months this necessitates continued external financing or partnerships, raising dilution risk and potentially forcing prioritization of programs, which could delay development timelines and reduce optionality.

Sernova Business Overview & Revenue Model

Company Description

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

How the Company Makes Money

Sernova primarily generates revenue through the development and potential commercialization of its Cell Pouch System and associated therapeutic cells. The company could earn income through licensing agreements, partnerships, and collaborations with other biotech or pharmaceutical companies interested in integrating Sernova's technology into their treatment pipelines. Additionally, Sernova may receive milestone payments and royalties from these partners as their therapeutics progress through clinical trials and toward market approval. The company may also benefit from research grants and government funding to support its innovation and development efforts.

Sernova Financial Statement Overview

Summary

Pre-revenue with continuing losses, despite meaningful improvement in net loss and operating cash burn. Balance-sheet risk is elevated due to negative equity, sharply higher debt in 2025, and very low reported assets, implying ongoing financing/dilution risk.

Income Statement

The company reports no revenue across the provided annual periods, consistent with a development-stage biotechnology profile, and losses remain sizable. Net losses improved materially from 2023 (-$39.0M) to 2024 (-$32.2M) and further to 2025 (-$15.7M), indicating meaningful cost control and/or reduced spending, but profitability is still far from break-even. Gross profit is negative in most years, reinforcing the lack of commercial scale and ongoing operating burn.

Balance Sheet

Balance sheet strength has deteriorated notably: shareholders’ equity moved from positive in 2023 ($12.5M) to negative in 2024 (-$13.0M) and further to negative in 2025 (-$25.1M), which is a key financial risk signal. Debt increased sharply in 2025 (to ~$17.3M from ~$0.6M in 2024), while total assets fell to ~$0.8M, implying a much tighter capital position. While leverage ratios become difficult to interpret with negative equity, the combination of rising debt and negative equity increases refinancing and dilution risk.

Cash Flow

Cash burn remains heavy, but the trajectory improved: operating cash outflow decreased from -$30.3M (2023) to -$19.0M (2024) and -$10.9M (2025). Free cash flow is similarly negative and declined in 2025 versus 2024 (about -26% year over year), indicating continued funding needs despite a smaller burn rate. Overall, cash generation is not yet self-sustaining, and ongoing external capital is likely required.

Breakdown	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-342.59K	0.00	-445.55K	-440.00K	-267.20K
EBITDA	-14.74M	-31.25M	-40.19M	-24.54M	-6.60M
Net Income	-15.74M	-32.19M	-39.00M	-24.54M	-7.02M
Balance Sheet
Total Assets	764.23K	7.53M	22.11M	52.48M	29.82M
Cash, Cash Equivalents and Short-Term Investments	265.00K	6.01M	19.81M	49.78M	27.87M
Total Debt	17.28M	569.94K	136.12K	275.98K	393.35K
Total Liabilities	25.84M	20.48M	9.59M	4.88M	1.75M
Stockholders Equity	-25.08M	-12.96M	12.51M	47.61M	28.07M
Cash Flow
Free Cash Flow	-10.91M	-18.90M	-30.44M	-14.75M	-6.86M
Operating Cash Flow	-10.91M	-18.90M	-30.34M	-14.42M	-6.84M
Investing Cash Flow	24.96K	11.12M	34.78M	-46.34M	-228.78K
Financing Cash Flow	5.14M	5.07M	503.46K	36.66M	31.00M

Sernova Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SVA, the sentiment is Positive. The current price of 0.15 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.15, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 67.11 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SVA.

Sernova Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	62 Neutral	C$52.75M	95.68	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	45 Neutral	C$32.56M	-6.85	-8.01%	―	-26.81%	-161.24%
DTC	45 Neutral	C$35.00M	-6.55	―	―	―	72.92%
SVA	44 Neutral	C$47.14M	-3.13	―	―	―	54.38%
MIR	42 Neutral	C$45.61M	-17.16	―	―	-41.70%	-35.42%

Sernova Corporate Events

Sernova Amends Warrants to Extend Terms and Cut Exercise Prices for Investors

Sernova Biotherapeutics plans to amend terms on a large portion of its outstanding warrants, subject to TSX approval, in a move that adjusts both duration and pricing for non-insider holders. The company will extend the expiry of 19,977,050 warrants issued in 2024 at $0.30 by one year to March 3, 2027, while leaving insider-held warrants unchanged.

Sernova will also reprice 5,571,250 warrants issued in late 2025 from $0.40 to $0.25 and introduce an accelerated expiry feature triggered if the five-day volume-weighted average price exceeds $0.50. The amendments, effective March 6, 2026, are designed to make the warrants more attractive and potentially enhance the company’s flexibility in raising equity capital without immediately impacting insider positions.

The most recent analyst rating on (TSE:SVA) stock is a Sell with a C$0.13 price target. To see the full list of analyst forecasts on Sernova stock, see the TSE:SVA Stock Forecast page.